Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3324/haematol.2016.147595 http://scihub22266oqcxt.onion/10.3324/haematol.2016.147595 C5394877!5394877!27742768     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Haematologica 2016 ; 101 (11): 1295-305 Nephropedia Template TP {{tp|p=27742768|t=2016. Osteonecrosis in children with acute lymphoblastic leukemia |pdf=|usr=}}{{27742768}} gab.com Text Osteonecrosis in children with acute lymphoblastic leukemia JO: Haematologica http://www.kidney.de/pget.php?&tw=1&pmid=27742768 #FOAvip The morbidity and toxicity associated with current intensive treatment protocols for acute lymphoblastic leukemia in childhood become even more important as the vast majority of children can be cured and become long-term survivors. Osteonecrosis is one of the most common therapy-related and debilitating side effects of anti-leukemic treatment and can adversely affect long-term quality of life. Incidence and risk factors vary substantially between study groups and therapeutic regimens. We therefore analyzed 22 clinical trials of childhood acute lymphoblastic leukemia in terms of osteonecrosis incidence and risk factors. Adolescent age is the most significant risk factor, with patients >10 years old at the highest risk. Uncritical modification or even significant reduction of glucocorticoid dosage cannot be recommended at this stage. A novel and innovative approach to reduce osteonecrosis-associated morbidity might be systematic early screening for osteonecrosis by serial magnetic resonance images. However, discriminating patients at risk of functional impairment and debilitating progressive joint disease from asymptomatic patients still remains challenging. Twit Text FOAVip Osteonecrosis in children with acute lymphoblastic leukemia ????Haematologica http://www.kidney.de/pget.php?&tw=1&pmid=27742768 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27742768 #FOAvip English Wikipedia <ref>{{Cite pmid|27742768}}</ref> Osteonecrosis in children with acute lymphoblastic leukemia #MMPMID27742768 Kunstreich M; Kummer S; Laws HJ; Borkhardt A; Kuhlen M Haematologica 2016[Nov]; 101 (11): 1295-305 PMID27742768show ga The morbidity and toxicity associated with current intensive treatment protocols for acute lymphoblastic leukemia in childhood become even more important as the vast majority of children can be cured and become long-term survivors. Osteonecrosis is one of the most common therapy-related and debilitating side effects of anti-leukemic treatment and can adversely affect long-term quality of life. Incidence and risk factors vary substantially between study groups and therapeutic regimens. We therefore analyzed 22 clinical trials of childhood acute lymphoblastic leukemia in terms of osteonecrosis incidence and risk factors. Adolescent age is the most significant risk factor, with patients >10 years old at the highest risk. Uncritical modification or even significant reduction of glucocorticoid dosage cannot be recommended at this stage. A novel and innovative approach to reduce osteonecrosis-associated morbidity might be systematic early screening for osteonecrosis by serial magnetic resonance images. However, discriminating patients at risk of functional impairment and debilitating progressive joint disease from asymptomatic patients still remains challenging. äOsteonecrosis in children with acute lymphoblastic leukemia (epmc).pdf DeepDyve Pubget Overpricing